| Dr Charles Chris Spielman, MD | |
|
2 Village Dr, Cape Heart Clinic, Cape May Court House, NJ 08210 | |
| (609) 465-7517 | |
| (609) 465-2448 |
| Full Name | Dr Charles Chris Spielman |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 53 Years |
| Location | 2 Village Dr, Cape May Court House, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851549356 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 25MA08200000 (New Jersey) | Secondary |
| 207R00000X | Internal Medicine | 25MA08200000 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cape Regional Medical Center Inc | Cape may court house, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Suketu Nanavati Md Pa | 6002074440 | 2 |
News Archive
The U.S. Food and Drug Administration today approved Ultomiris (ravulizumab) injection for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.
Devising a novel method to identify potential genetic regulators in planarian stem cells, Whitehead Institute scientists have determined which of those genes affect the two main functions of stem cells. Three of the genes are particularly intriguing because they code for proteins similar to those known to regulate mammalian embryonic stem cells. Such genetic similarity makes planarians an even more attractive model for studying stem cell biology in vivo.
Aegera Therapeutics Inc. released today encouraging survival data from the Phase 1 portion of its Phase 1-2 Study of the novel targeted therapeutic, AEG35156, given in combination with sorafenib in patients with advanced hepatocellular carcinoma (primary liver cancer).
The American Brain Tumor Association will again host its annual Path to Progress 5K Run/Walk on Saturday, May 22, 2010 at Soldier Field in Chicago.
› Verified 9 days ago
| Entity Name | Cape Cardiology Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073502050 PECOS PAC ID: 1456427517 Enrollment ID: O20090115000196 |
News Archive
The U.S. Food and Drug Administration today approved Ultomiris (ravulizumab) injection for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.
Devising a novel method to identify potential genetic regulators in planarian stem cells, Whitehead Institute scientists have determined which of those genes affect the two main functions of stem cells. Three of the genes are particularly intriguing because they code for proteins similar to those known to regulate mammalian embryonic stem cells. Such genetic similarity makes planarians an even more attractive model for studying stem cell biology in vivo.
Aegera Therapeutics Inc. released today encouraging survival data from the Phase 1 portion of its Phase 1-2 Study of the novel targeted therapeutic, AEG35156, given in combination with sorafenib in patients with advanced hepatocellular carcinoma (primary liver cancer).
The American Brain Tumor Association will again host its annual Path to Progress 5K Run/Walk on Saturday, May 22, 2010 at Soldier Field in Chicago.
› Verified 9 days ago
| Entity Name | Suketu Nanavati Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568600385 PECOS PAC ID: 6002074440 Enrollment ID: O20120215000094 |
News Archive
The U.S. Food and Drug Administration today approved Ultomiris (ravulizumab) injection for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.
Devising a novel method to identify potential genetic regulators in planarian stem cells, Whitehead Institute scientists have determined which of those genes affect the two main functions of stem cells. Three of the genes are particularly intriguing because they code for proteins similar to those known to regulate mammalian embryonic stem cells. Such genetic similarity makes planarians an even more attractive model for studying stem cell biology in vivo.
Aegera Therapeutics Inc. released today encouraging survival data from the Phase 1 portion of its Phase 1-2 Study of the novel targeted therapeutic, AEG35156, given in combination with sorafenib in patients with advanced hepatocellular carcinoma (primary liver cancer).
The American Brain Tumor Association will again host its annual Path to Progress 5K Run/Walk on Saturday, May 22, 2010 at Soldier Field in Chicago.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Charles Chris Spielman, MD 2 Village Dr, Cape Heart Clinic, Cape May Court House, NJ 08210-1939 Ph: (609) 465-7517 | Dr Charles Chris Spielman, MD 2 Village Dr, Cape Heart Clinic, Cape May Court House, NJ 08210 Ph: (609) 465-7517 |
News Archive
The U.S. Food and Drug Administration today approved Ultomiris (ravulizumab) injection for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.
Devising a novel method to identify potential genetic regulators in planarian stem cells, Whitehead Institute scientists have determined which of those genes affect the two main functions of stem cells. Three of the genes are particularly intriguing because they code for proteins similar to those known to regulate mammalian embryonic stem cells. Such genetic similarity makes planarians an even more attractive model for studying stem cell biology in vivo.
Aegera Therapeutics Inc. released today encouraging survival data from the Phase 1 portion of its Phase 1-2 Study of the novel targeted therapeutic, AEG35156, given in combination with sorafenib in patients with advanced hepatocellular carcinoma (primary liver cancer).
The American Brain Tumor Association will again host its annual Path to Progress 5K Run/Walk on Saturday, May 22, 2010 at Soldier Field in Chicago.
› Verified 9 days ago
Dr. Christopher G Zitnay, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 2 Stone Harbor Blvd, Cape May Court House, NJ 08210 Phone: 609-465-2000 | |
Mark Robert Sorensen, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 211 S Main St, Suite 205, Cape May Court House, NJ 08210 Phone: 609-463-0800 Fax: 609-463-0957 | |
Renjy Vattasseril, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 217 N Main St, Suite 102, Cape May Court House, NJ 08210 Phone: 609-536-8010 Fax: 609-536-8053 | |
Sahil R Shaikh, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 Stone Harbor Blvd, Cape May Court House, NJ 08210 Phone: 609-463-2803 Fax: 609-463-4991 | |
Dr. Holli Ami Barth, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 Stone Harbor Blvd, Cape May Court House, NJ 08210 Phone: 609-463-2498 | |
Michael N Boriss, DO Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 217 N Main St, Suite 205, Cape May Court House, NJ 08210 Phone: 609-463-2755 Fax: 609-463-2757 | |
Dr. Suketu H Nanavati, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 Village Dr, Cape May Court House, NJ 08210 Phone: 609-465-7517 |